Brief: VistaGen Receives New European Patent For AV-101
06/04/2023 13:36
April 6 (Reuters) - VistaGen Therapeutics Inc VTGN.O :
* VISTAGEN RECEIVES NEW EUROPEAN PATENT FOR AV-101
* VISTAGEN THERAPEUTICS - NEW EUROPEAN PATENT IS A
COUNTERPART TO
PREVIOUSLY GRANTED U.S. PATENT 11,427,530 AND WILL BE IN EFFECT
UNTIL AT LEAST 2039
Source text for Eikon: ID:nBw7BSd92a
Further company coverage: VTGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vistagen Therapeutics
See all newsBrief: Vistagen TherapeuticsSays Fasedienol Nasal Spray Well-Tolerated With No New Drug-Related Safety Findings After 12 Months
VistaGen Q1 revenue rises on licensing agreement expiration
Brief: VistaGen Q1 EPS USD -0.3
Vistagen Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Vistagen Appoints Douglas J. Williamson To Its Board Of Directors